Autopsy report · NCT01134315

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

“Terminated after FDA agreement.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 11 months before it stopped.
• 61 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Sponsor

AbbVie (prior sponsor, Abbott)

Sponsor type

Industry

Conditions

Secondary Hyperparathyroidism; End-Stage Renal Disease

Interventions

Paricalcitol; Calcitriol

Participants

61

Sites

18

Countries

United States

Trials that died the same way

• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
  “Terminated due to unacceptable toxicity” (76% match in meaning)
• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
  “Terminated due to the sponsor's decision.” (75% match in meaning)
• Mortality Due to Malignancy in Patients With Idiopathic Venous Thromboembolism
  “Terminated because of futility to continue, after planned interim analysis.” (74% match in meaning)
• GSK2983559 First Time in Human Study
  “Terminated due to non clinical toxicology findings and reduced safety margins.” (73% match in meaning)
• Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
  “Terminated due to lack of efficacy” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.